In this issue:
Pirtobrutinib in relapsed/refractory B-cell malignancies
Leukaemia selection
Postreinduction consolidation with blinatumomab in young people with first B-ALL relapse
Vemurafenib + rituximab in refractory/relapsed hairy-cell leukaemia
Chemotherapy vs. allogeneic SCT in high-risk Pwwh– ALL
Implications of MRD at two timepoints after chemotherapy for AML
Inotuzumab ozogamicin for relapsed/refractory Ph+ ALL
Lymphoma selection
End-of-treatment PET/CT predicts PFS/OS in DLBCL after first-line treatment
R-CHOP dose intensity and survival in DLBCL
Non-Hodgkin’s lymphoma during pregnancy
Adding lenalidomide to R-CHOP in newly diagnosed DLBCL
Please login below to download this issue (PDF)